Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that they have entered into a ...

Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision ...

What’s available: Nirsevimab (brand name Beyfortus) is a monoclonal antibody given ... Three RSV vaccines are approved for use in the U.S. in adults ages 60 and older: GSK's Arexvy, Pfizer's Abrysvo, ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

On Tuesday night, October 1st, at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 16th annual Trailblazer Awards. In total, PM360, a leading life sciences ...